Zurcher Kantonalbank Zurich Cantonalbank Sells 2,612 Shares of Qiagen NV (QGEN)

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Qiagen NV (NASDAQ:QGEN) by 3.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 74,202 shares of the company’s stock after selling 2,612 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Qiagen NV were worth $2,159,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Opus Point Partners Management LLC increased its position in shares of Qiagen NV by 1.0% in the fourth quarter. Opus Point Partners Management LLC now owns 111,683 shares of the company’s stock worth $3,129,000 after buying an additional 1,118 shares during the last quarter. Parametrica Management Ltd increased its position in Qiagen NV by 38.7% in the first quarter. Parametrica Management Ltd now owns 10,107 shares of the company’s stock worth $293,000 after buying an additional 2,818 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Qiagen NV during the third quarter worth $351,000. BlackRock Investment Management LLC increased its position in Qiagen NV by 6.5% in the third quarter. BlackRock Investment Management LLC now owns 118,904 shares of the company’s stock worth $3,263,000 after buying an additional 7,205 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Qiagen NV by 49.4% in the fourth quarter. AQR Capital Management LLC now owns 64,175 shares of the company’s stock worth $1,801,000 after buying an additional 21,234 shares in the last quarter. 60.68% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Qiagen NV (NASDAQ:QGEN)

Qiagen NV (NASDAQ:QGEN) traded up 1.71% during midday trading on Friday, hitting $32.67. The stock had a trading volume of 462,034 shares. The stock has a 50-day moving average price of $29.92 and a 200 day moving average price of $29.12. Qiagen NV has a 12-month low of $20.71 and a 12-month high of $32.80. The firm has a market cap of $7.44 billion, a P/E ratio of 90.75 and a beta of 1.05.

COPYRIGHT VIOLATION NOTICE: “Zurcher Kantonalbank Zurich Cantonalbank Sells 2,612 Shares of Qiagen NV (QGEN)” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.themarketsdaily.com/2017/05/19/zurcher-kantonalbank-zurich-cantonalbank-sells-2612-shares-of-qiagen-nv-qgen.html.

QGEN has been the topic of a number of recent research reports. Commerzbank Ag reissued a “buy” rating on shares of Qiagen NV in a report on Thursday, January 19th. Deutsche Bank AG reissued a “buy” rating on shares of Qiagen NV in a report on Monday, January 30th. Jefferies Group LLC reissued a “hold” rating on shares of Qiagen NV in a report on Friday, February 3rd. DZ Bank AG reissued a “neutral” rating on shares of Qiagen NV in a report on Monday, February 6th. Finally, Zacks Investment Research raised Qiagen NV from a “sell” rating to a “hold” rating in a report on Friday, March 17th. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Qiagen NV currently has a consensus rating of “Hold” and an average price target of $28.36.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply